Exceptional Trial Permits for Amoéba's Biofungicide in the Netherlands

Amoéba, a French company specializing in natural microbiological solutions, has announced the granting of two trial permits in the Netherlands for its biofungicide, AXPERA. These permits, issued by the CTGB, allow for large-scale trials on a variety of crops, enabling consumption of the produce.

The Netherlands, with its robust greenhouse sector, is a crucial market for Amoéba. The country's greenhouse cultivation expertise provides an ideal scenario to showcase AXPERA's efficacy against powdery mildew and downy mildew, key plant diseases.

Working in collaboration with Koppert, a leader in biological solutions, these trials aim to accelerate the agronomic validation of AXPERA. This step serves as a precursor to obtaining final marketing authorizations in both France and the Netherlands.